Search | VHL Search Portal

1.

Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma.

Bröckelmann, Paul J.

Br J Haematol ; 2024 May 16.

Article in English | MEDLINE | ID: mdl-38757338

2.

Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma.

Grund, Johanna; Iben, Katharina; Reinke, Sarah; Bühnen, Ina; Plütschow, Annette; Müller-Meinhard, Berit; Garcia Marquez, Maria A; Schlößer, Hans A; von Tresckow, Bastian; Kellermeier, Fabian; Borchmann, Peter; Engert, Andreas; Bröckelmann, Paul J; Klapper, Wolfram.

Br J Haematol ; 201(6): 1097-1102, 2023 06.

Article in English | MEDLINE | ID: mdl-36921595

3.

9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.

Gerhard-Hartmann, Elena; Goergen, Helen; Bröckelmann, Paul J; Mottok, Anja; Steinmüller, Tabea; Grund, Johanna; Zamò, Alberto; Ben-Neriah, Susana; Sasse, Stephanie; Borchmann, Sven; Fuchs, Michael; Borchmann, Peter; Reinke, Sarah; Engert, Andreas; Veldman, Johanna; Diepstra, Arjan; Klapper, Wolfram; Rosenwald, Andreas.

Br J Haematol ; 196(1): 116-126, 2022 01.

Article in English | MEDLINE | ID: mdl-34520052

4.

Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).

Gillessen, Sarah; Hüttmann, Andreas; Vucinic, Vladan; Müller, Horst; Plütschow, Annette; Viardot, Andreas; Topp, Max S; Kobe, Carsten; Böll, Boris; Eichenauer, Dennis A; Sasse, Stephanie; Haverkamp, Heinz; Schmitz, Christine; Borchmann, Sven; Bröckelmann, Paul J; Heger, Jan-Michel; Fuchs, Michael; Engert, Andreas; Borchmann, Peter; von Tresckow, Bastian.

Br J Haematol ; 196(3): 606-616, 2022 02.

Article in English | MEDLINE | ID: mdl-34775591

5.

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.

Reinke, Sarah; Bröckelmann, Paul J; Iaccarino, Ingram; Garcia-Marquez, Maria; Borchmann, Sven; Jochims, Franziska; Kotrova, Michaela; Pal, Karol; Brüggemann, Monika; Hartmann, Elena; Sasse, Stephanie; Kobe, Carsten; Mathas, Stephan; Soekler, Martin; Keller, Ulrich; Bormann, Matthias; Zimmermann, Andreas; Richter, Julia; Fuchs, Michael; von Tresckow, Bastian; Borchmann, Peter; Schlößer, Hans; von Bergwelt-Baildon, Michael; Rosenwald, Andreas; Engert, Andreas; Klapper, Wolfram.

Blood ; 136(25): 2851-2863, 2020 12 17.

Article in English | MEDLINE | ID: mdl-33113552

6.

JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).

Gillessen, Sarah; Pluetschow, Annette; Vucinic, Vladan; Ostermann, Helmut; Kobe, Carsten; Bröckelmann, Paul J; Böll, Boris; Eichenauer, Dennis A; Heger, Jan-Michel; Borchmann, Sven; Fuchs, Michael; Borchmann, Peter; Engert, Andreas; von Tresckow, Bastian.

Eur J Haematol ; 109(6): 728-735, 2022 Dec.

Article in English | MEDLINE | ID: mdl-36056778

7.

Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma.

Graef, Claus Moritz; Gödel, Philipp; Falderbaum, Philipp; Balke-Want, Hyatt; Simon, Florian; Sieg, Noëlle; Naendrup, Jan-Hendrik; Neumann, Marie Anne-Catherine; Gillessen, Sarah; Bröckelmann, Paul J; Eichenauer, Dennis A; Borchmann, Peter; von Tresckow, Bastian; Heger, Jan-Michel.

Eur J Haematol ; 108(5): 403-412, 2022 May.

Article in English | MEDLINE | ID: mdl-35090068

8.

Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.

Kreuzberger, Nina; Hirsch, Caroline; Andreas, Marike; Böhm, Lena; Bröckelmann, Paul J; Di Cristanziano, Veronica; Golinski, Martin; Hausinger, Renate Ilona; Mellinghoff, Sibylle; Lange, Berit; Lischetzki, Tina; Kappler, Verena; Mikolajewska, Agata; Monsef, Ina; Park, Yun Soo; Piechotta, Vanessa; Schmaderer, Christoph; Stegemann, Miriam; Vanshylla, Kanika; Weber, Florencia; Weibel, Stephanie; Stephani, Caspar; Skoetz, Nicole.

Cochrane Database Syst Rev ; 8: CD015021, 2022 08 09.

Article in English | MEDLINE | ID: mdl-35943061

9.

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.

Borchmann, Peter; Plütschow, Annette; Kobe, Carsten; Greil, Richard; Meissner, Julia; Topp, Max S; Ostermann, Helmut; Dierlamm, Judith; Mohm, Johannes; Thiemer, Julia; Sökler, Martin; Kerkhoff, Andrea; Ahlborn, Miriam; Halbsguth, Teresa V; Martin, Sonja; Keller, Ulrich; Balabanov, Stefan; Pabst, Thomas; Vogelhuber, Martin; Hüttmann, Andreas; Wilhelm, Martin; Zijlstra, Josée M; Moccia, Alden; Kuhnert, Georg; Bröckelmann, Paul J; von Tresckow, Bastian; Fuchs, Michael; Klimm, Beate; Rosenwald, Andreas; Eich, Hans; Baues, Christian; Marnitz, Simone; Hallek, Michael; Diehl, Volker; Dietlein, Markus; Engert, Andreas.

Lancet Oncol ; 22(2): 223-234, 2021 02.

Article in English | MEDLINE | ID: mdl-33539742

10.

Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routine.

Sieg, Noëlle; Naendrup, Jan-Hendrik; Gödel, Philipp; Balke-Want, Hyatt; Simon, Florian; Deckert, Martina; Gillessen, Sarah; Kreissl, Stefanie; Bröckelmann, Paul J; Borchmann, Peter; von Tresckow, Bastian; Heger, Jan-Michel.

Eur J Haematol ; 107(2): 202-210, 2021 Aug.

Article in English | MEDLINE | ID: mdl-33960535

11.

AXL-erating mantle cell lymphoma treatment.

Bröckelmann, Paul J.

Blood ; 142(17): 1411-1412, 2023 10 26.

Article in English | MEDLINE | ID: mdl-37883111

12.

Balancing risk and benefit in early-stage classical Hodgkin lymphoma.

Bröckelmann, Paul J; Sasse, Stephanie; Engert, Andreas.

Blood ; 131(15): 1666-1678, 2018 04 12.

Article in English | MEDLINE | ID: mdl-29500174

13.

Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.

Bröckelmann, Paul J; McMullen, Suzanne; Wilson, J Ben; Mueller, Kerstin; Goring, Sarah; Stamatoullas, Aspasia; Zagadailov, Erin; Gautam, Ashish; Huebner, Dirk; Dalal, Mehul; Illidge, Tim.

Br J Haematol ; 184(2): 202-214, 2019 01.

Article in English | MEDLINE | ID: mdl-30239982

14.

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.

Böll, Boris; Goergen, Helen; Behringer, Karolin; Bröckelmann, Paul J; Hitz, Felicitas; Kerkhoff, Andrea; Greil, Richard; von Tresckow, Bastian; Eichenauer, Dennis A; Bürkle, Carolin; Borchmann, Sven; Fuchs, Michael; Diehl, Volker; Engert, Andreas; Borchmann, Peter.

Blood ; 127(18): 2189-92, 2016 05 05.

Article in English | MEDLINE | ID: mdl-26834240

15.

Unfolding the potential of anti-programmed cell death protein 1 blockade in Hodgkin lymphoma - combination and personalisation?

Bröckelmann, Paul J.

Br J Haematol ; 196(1): 10-12, 2022 01.

Article in English | MEDLINE | ID: mdl-34649300

16.

Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefits.

Bröckelmann, Paul J; Borchmann, Peter.

Br J Haematol ; 197(5): 515-517, 2022 06.

Article in English | MEDLINE | ID: mdl-35262911

17.

Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.

Momotow, Jesko; Bühnen, Ina; Trautmann-Grill, Karolin; Kobbe, Guido; Hahn, Dennis; Schroers, Roland; Heinrich, Bernhard; Gaska, Tobias; Forstbauer, Helmut; Schmidt, Burkhard; Boger, Regina; Hüttmann, Andreas; Heil, Gerhard; Kraemer, Doris M; Krüger, William; Zeremski, Vanja; Grobe, Norbert; Jentsch-Ullrich, Kathleen; Griesinger, Frank; Fuchs, Michael; von Tresckow, Bastian; Borchmann, Peter; Engert, Andreas; Bröckelmann, Paul J.

Br J Haematol ; 198(2): 401-404, 2022 07.

Article in English | MEDLINE | ID: mdl-35538912

18.

The emerging role of immune checkpoint inhibition in malignant lymphoma.

Hude, Ida; Sasse, Stephanie; Engert, Andreas; Bröckelmann, Paul J.

Haematologica ; 102(1): 30-42, 2017 01.

Article in English | MEDLINE | ID: mdl-27884973

19.

Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.

Bröckelmann, Paul J; Zagadailov, Erin A; Corman, Shelby L; Chirikov, Viktor; Johnson, Courtney; Macahilig, Cynthia; Seal, Brian; Dalal, Mehul R; Illidge, Tim.

Eur J Haematol ; 99(6): 553-558, 2017 Dec.

Article in English | MEDLINE | ID: mdl-28949403

20.

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.

Cheah, Chan Y; Bröckelmann, Paul J; Chihara, Dai; Moskowitz, Alison J; Engert, Andreas; Jerkeman, Mats; El-Galaly, Tarec C; Augustson, Bradley; Vose, Julie; Bartlett, Nancy L; Villa, Diego; Connors, Joseph M; Feldman, Tatyana; Pinnix, Chelsea C; Milgrom, Sarah A; Dabaja, Bouthaina; Oki, Yasuhiro; Fanale, Michelle A.

Am J Hematol ; 91(9): 894-9, 2016 09.

Article in English | MEDLINE | ID: mdl-27222367

VHL Search Portal

Information and Knowledge for Health

Config filters

Your selection (0)

Export format:

Export:

Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma.

Low B-cell content is associated with a CD73-low tumour microenvironment and unfavourable prognosis in classic Hodgkin lymphoma.

9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.

Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.

JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).

Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma.

Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.

Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routine.

AXL-erating mantle cell lymphoma treatment.

Balancing risk and benefit in early-stage classical Hodgkin lymphoma.

Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.

Unfolding the potential of anti-programmed cell death protein 1 blockade in Hodgkin lymphoma - combination and personalisation?

Navigating increasingly individualised Hodgkin lymphoma treatments to optimally balance risks and benefits.

Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.

The emerging role of immune checkpoint inhibition in malignant lymphoma.

Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.